Amneal [AMRX] vs Zoetis [ZTS] Detailed Stock Comparison

Amneal Pharmaceuticals Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amneal Pharmaceuticals Inc. wins in 5 metrics, Zoetis Inc. wins in 15 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amneal Pharmaceuticals Inc. Zoetis Inc. Better
P/E Ratio (TTM) 63.23 19.58 Zoetis Inc.
Price-to-Book Ratio -57.42 15.04 Zoetis Inc.
Debt-to-Equity Ratio 45,095.52 279.59 Zoetis Inc.
PEG Ratio -0.30 2.81 Zoetis Inc.
EV/EBITDA 10.64 13.96 Amneal Pharmaceuticals Inc.
Profit Margin (TTM) 2.39% 28.24% Zoetis Inc.
Operating Margin (TTM) 14.06% 34.69% Zoetis Inc.
EBITDA Margin (TTM) 14.06% 34.69% Zoetis Inc.
Return on Equity -101.02% 65.99% Zoetis Inc.
Return on Assets (TTM) 7.32% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $225.64M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 109.03% -51.58% Amneal Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 1.47 5.26 Amneal Pharmaceuticals Inc.
Enterprise Value $6.86B $56.75B Zoetis Inc.
EV/Revenue Ratio 2.27 6.00 Amneal Pharmaceuticals Inc.
Gross Profit Margin (TTM) 36.50% 70.17% Zoetis Inc.
Revenue per Share (TTM) $10 $21 Zoetis Inc.
Earnings per Share (Diluted) $0.22 $6.02 Zoetis Inc.
Beta (Stock Volatility) 1.32 0.97 Zoetis Inc.
Short % of Float 3.47% 4.06% Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

AMRX
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amneal Pharmaceuticals Inc.0.25%18.45%36.13%36.01%30.34%28.28%
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amneal Pharmaceuticals Inc.109.03%497.79%211.54%10.20%10.20%10.20%
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%

Performance & Financial Health Analysis: Amneal Pharmaceuticals Inc. vs Zoetis Inc.

MetricAMRXZTS
Market Information
Market Cap i$4.15B$49.75B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,402,9902,727,710
90 Day Avg. Volume i1,913,7233,835,940
Last Close$16.24$167.10
52 Week Range$7.66 - $16.61$139.70 - $200.33
% from 52W High-2.23%-16.59%
All-Time High$24.48 (Aug 20, 2018)$249.27 (Dec 27, 2021)
% from All-Time High-33.66%-32.96%
Growth Metrics
Quarterly Revenue Growth0.12%0.03%
Quarterly Earnings Growth0.11%0.04%
Financial Health
Profit Margin (TTM) i0.02%0.28%
Operating Margin (TTM) i0.14%0.35%
Return on Equity (TTM) i-1.01%0.66%
Debt to Equity (MRQ) i45,095.52279.59
Cash & Liquidity
Book Value per Share (MRQ)$-0.23$7.84
Cash per Share (MRQ)$0.91$5.48
Operating Cash Flow (TTM) i$339.99M$2.90B
Levered Free Cash Flow (TTM) i$197.07M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Amneal Pharmaceuticals Inc. vs Zoetis Inc.

MetricAMRX (Apr 22, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i63.2319.58
Forward P/E i11.7815.61
PEG Ratio i-0.302.81
Price to Sales (TTM) i1.475.26
Price to Book (MRQ) i-57.4215.04
Market Capitalization
Market Capitalization i$4.15B$49.75B
Enterprise Value i$6.86B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i2.276.00
Enterprise to EBITDA i10.6413.96
Risk & Other Metrics
Beta i1.320.97
Book Value per Share (MRQ) i$-0.23$7.84

Financial Statements Comparison: Amneal Pharmaceuticals Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMRX (2025)ZTS (2025)
Revenue/Sales i3.02B9.47B
Cost of Goods Sold i1.91B2.67B
COGS % of Revenue i63.1%28.2%
Gross Profit i1.11B6.80B
Gross Margin i36.9%71.8%
Research & Development i193.81M698.00M
Operating Income (EBIT) i397.91M3.60B
Operating Margin i13.2%38.0%
EBITDA i606.64M4.17B
EBITDA Margin i20.1%44.1%
Pre-Tax Income i139.21M3.36B
Pre-Tax Income % of Revenue i4.6%35.5%
Income Tax i11.28M687.00M
Income Tax % of Revenue i0.4%7.3%
Net Income (Profit) i127.93M2.67B
Profit Margin i4.2%28.2%

Balance Sheet & Liquidity Metrics

MetricAMRX (2025)ZTS (2025)
Cash & Equivalents i282.03M2.31B
Total Current Assets i1.91B6.77B
Total Current Assets % of Revenue i63.3%71.5%
Total Current Liabilities i881.63M2.24B
Total Current Liabilities % of Revenue i29.2%23.6%
Long-Term Debt i2.67B9.24B
Long-Term Debt % of Revenue i88.4%97.6%
Total Shareholders Equity i-71.33M3.33B
Retained Earnings i-535.01M13.74B
Retained Earnings % of Revenue i-17.7%145.2%
Property, Plant & Equipment i107.38M288.00M

Cash Flow Statement Comparison

MetricAMRX (2025)ZTS (2025)
Operating Cash Flow i256.93M2.78B
Operating Cash Flow % of Revenue i8.5%29.3%
Capital Expenditures i-96.75MN/A
Free Cash Flow i225.64M2.28B
FCF Margin i7.5%24.1%
Debt Repayment i-2.81B-1.35B
Common Stock Repurchase iN/A-3.24B

Short Interest & Institutional Ownership Analysis

MetricAMRXZTS
Shares Short i7.19M15.12M
Short Ratio i3.183.60
Short % of Float i3.47%4.06%
Shares Outstanding i314.57M424.93M
Float Shares i176.28M421.29M
% Held by Insiders i44.04%0.15%
% Held by Institutions i49.74%101.50%
% Held by Public i6.22%-1.65%

Dividend Analysis & Yield Comparison: Amneal Pharmaceuticals Inc. vs Zoetis Inc.

MetricAMRXZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026